Acumen research and consulting estimates that the global anti-rheumatics market is anticipated to reach market size of around US$ 72,000 Mn by 2027 and is anticipated to grow at a CAGR of around 3% in terms of revenue during the forecast period 2020 – 2027.
The area of rheumatic disease treatment is multidisciplinary and includes disorders involving limbs, connective tissue, ligaments, tendon, cartilage, muscle and bone marked by chronic pain and a reduced activity. Most rheumatic diseases are treated with generic pain management therapies and there are no cures for any of the main indications which leave a significant lack of satisfaction with the need for improving disease-modification drugs.
Growing rheumatoid arthritis and the rise in the geriatric population worldwide are key factors that drive the development of the global rheumatic industry. Another big factor in the rise of the anti-rheumatic industry is an increase in malnutrition in the country. However the market development is hampered by adverse drug-related effects and rising cost of biologics and bio-similars. Instead, biosimilars and other biological technologies have been anticipated to deliver lucrative growth prospects for the anti-rheumatic market.
NSAIDs, by Drug Class is Expected to be the Largest Segment Over the Forecast Period
The symptomatic diagnosis of rheumatic conditions is commonly treated byNSAIDs. In the treatment of mild to extreme rheumatoid arthritis, disease-modifying anti-rheumatoid medications (DMARDs) are still used as the monetary system. In comparison to standard DMARDs, NSAIDs offer symptomatic stimulation; while biological drugs enhance rheumatoid arthritis treatment. Globally, the prevalence of the disease increases segment development. The use and development of NSAIDs is expected to satisfy healthy demand and supply over the forecast period with the growing number of cases for Arthritis. According to a study, in 2017, morbidity and mortality was around 78 million in U.S.(26% U.S. adults 18 years of age or older); while in 2040, the figure is projected to rise gradually in arthritis, thereby increasing the anticipated market growth of NSAIDs.
The market research study on “Anti-Rheumatics Market (By Drug Class: Disease Modifying Anti-rheumatics Drugs (DMARD’S), Nonsteroidal Anti-inflammatory Drugs (NSAID’S), Corticosteroids, Uric Acid Drugs, and Others; By Type: Prescription-based Drugs, Over-the-counter Drugs; By Distribution Channel: Retail, Pharmacies, Online Pharmacies, Hospital Pharmacies; By End-User: Hospitals & Clinics, Ambulatory Surgical Centers, Healthcare Specialty Process) - Global Industry, Analysis, Market Size, Opportunities and Forecast, 2020 - 2027” offers detailed insights on the global anti-rheumatics market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report also provides competitive landscape to understand the current stance of particular player. The report provides insights on global anti-rheumatics market are drug class, type, distribution channel and major geographic regions. The anti-rheumatics market analysis is provided for major regional markets including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. For each region, the market size for different segments has been covered under the scope of report.
North America accounted for largest market share of global anti-rheumatics market in 2019 9 and the also supply of anti-rheumatics is expected to continue market development during forecast period. Another major factor which fuels the growth of the anti-rheumatic market in North America is the increase in the geriatric population of the region. On the other hand, Asia-Pacific is estimated to register the largest growth in anti-rheumatics awareness over the projected period. The ever-changing life science industry fuels market development in emerging economies like India, China and Malaysia..
Major players included in this report Johnson & Johnson, Pfizer, Inc., Bristol-Myers Squibb Company, Celegene Corporations, F. Hoffmann-La Roche Ltd., MedImmune, LLC, Biogen Inc., Celltrion Inc., Takeda Pharmaceutical Company Ltd., Amgen Inc. and others. Many of the prescription products for rheumatoid arthritis are developed by these main players. The market players in this market have developed their position and these players have a wide variety of products and a broad range of distribution channels across the globe. . Advanced medical technology has seen major changes in diagnosis and treatment to enhance the performance of manufacturers of anti-rheumatics in the Asia Pacific region. The new products in the Asia-Pacific rheumatoid arthritis market are an antiIL6 human mAb, Sirukumab, Peficitinib, Upadacitinib and Filgotinib, which are Olokizumab, RCT18, JAK1 inhibitors and an antiIL6 humanized IgG4 mAb a recombinant human Blymphocyte stimulating factor (BLyS) receptor antibody fusion protein.
The global anti-rheumatics market is segmented as below:
Market By Drug Class
Market By Type
Market By Distribution Channel
Market By End-User
Anti-Rheumatics Market By Geography
Middle East & Africa
Rise in incidence of rheumatoid arthritis and surge in geriatric population across the globe is the major drivers for the growth of the anti-rheumatics market.
Side effects associated with the medication are a major factor expected to restraint the growth of the market.
The market value of anti-rheumatics is anticipated to be hit around US$ 72,000 Mn in 2027.
The anti-rheumatics market is anticipated to grow around 3% CAGR amid the forecast period 2020-2027.
North America held maximum share in 2019.
Asia Pacific is projected to grow at a fast pace during forecast period from 2020-2027.
Nonsteroidal Anti-inflammatory Drugs (NSAID’S), by drug class is expected to be the largest segment over the forecast period.